Prenetics Global Limited cash flow statement PRE
In fiscal 2024, which ended Dec 31, 2024, Prenetics Global Limited used $28.9 million of cash from operations, down 109.8% from the year before. It spent $1.0 million on capital expenditures. Free cash flow was negative, at -$29.9 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
|---|---|---|---|
| Operating | |||
| Stock-based compensation |
7
-29.9%
|
10
-59.5%
|
26
|
| Operating cash flow |
-29
-109.8%
|
-14
-194.8%
|
15
|
| Investing | |||
| Capital expenditures |
1
+191.6%
|
0
-93.0%
|
5
|
| Investing cash flow |
39
+146.5%
|
-83
-79.8%
|
-46
|
| Financing | |||
| Financing cash flow |
-3
+28.9%
|
-5
-103.3%
|
143
|
| Change in cash | |||
| Effect of exchange rate |
0
-52.7%
|
0
+247.3%
|
-0
|
| Free cash flow |
-30
-111.8%
|
-14
-247.5%
|
10
|
| Per share | |||
| Free cash flow per share |
-2.39
|
—
|
—
|
| Ratios | |||
| Free cash flow margin |
-97.58%
|
-64.89%
|
72.68%
|
| Capital expenditures to revenue |
3.29%
|
1.59%
|
37.59%
|
| Stock-based compensation to revenue |
24.04%
|
48.27%
|
196.86%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRE (Nasdaq), PRENW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Quarry Bay, Hong Kong
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1876431
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.